Ocular Therapeutix (OCUL)
(Delayed Data from NSDQ)
$5.02 USD
+0.04 (0.80%)
Updated Jun 11, 2024 04:00 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
OCUL 5.02 +0.04(0.80%)
Will OCUL be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for OCUL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OCUL
Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround
Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 34.74%: Read This Before Placing a Bet
OCUL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates
Beat the Market Like Zacks: Walmart, Novo Nordisk, Procter & Gamble in Focus
Can VAALCO (EGY) Deliver Strong Q4 Earnings Performance?
Other News for OCUL
Adverum Biotechnologies appoints Ozden as CMO, Kiss to board of directors
Ocular Therapeutix® to Host Investor Day on June 13, 2024
Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix to eliminate 13% of company's workforce
Ocular Therapeutix: Betting On Axpaxli For A Major Market Breakthrough